This listing of claims will replace all prior versions, and listings, of claims in the application:

1-9. (Canceled)

10. (Previously presented) A method for treating an individual with impaired glucose tolerance who has not been diagnosed with non-insulin dependent diabetes mellitus (NIDDM), comprising:

administering to said individual a composition comprising a compound which binds to a receptor for glucagon-like peptide-1, thereby treating impaired glucose tolerance.

- 11. (Original) The method of claim 10 wherein the receptor binding compound is selected from (a) a peptide which comprises the amino acid sequence of glucagon-like peptide-1, and (b) a variant peptide comprising an amino acid sequence that differs from the sequence of glucagon-like peptide-1 by one or more substitutions, deletions or insertions.
- 12. (Original) The method of claim 11 wherein the receptor binding compound is glucagon-like peptide-1.
- 13. (Previously presented) The method of claim 11 wherein the receptor binding compound is glucagon-like peptide-1 (7-37) which has the sequence His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg Gly SEQ ID NO:3.
- 14. (Previously presented) The method of claim 11 wherein the receptor binding compound is glucagon-like peptide-1 (7-36) amide which has the sequence His

Okhorter 04/15/05 An